Chromosomal Microarray (CMA) Testing for the Evaluation of Products of Conception and Pregnancy Loss

Effective: June 1, 2018

Next Review: April 2019
Last Review: April 2018

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Chromosomal microarray (CMA) testing of products of conception, including fetal tissue or placental tissue, may be performed to evaluate the cause of isolated and recurrent early pregnancy loss (miscarriages) and later pregnancy loss (intrauterine fetal demise [IUFD]).

MEDICAL POLICY CRITERIA

Note: Please refer to the Cross References section below for genetic testing not addressed in this policy, including but not limited to, whole exome or genome sequencing, preimplantation diagnosis or screening, carrier screening, and single-gene testing.

I. Chromosomal microarray (CMA) testing of fetal tissue may be considered medically necessary when any of the following criteria are met:
   A. In cases of pregnancy loss at less than or equal to 20 weeks of gestation when there is a maternal history of recurrent pregnancy loss, defined as having two or more consecutive clinical pregnancy losses; OR
   B. In all cases of pregnancy loss after 20 weeks of gestation.
II. The use of CMA testing for products of conception or for pregnancy loss is considered investigational when Criteria I. above are not met.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

POLICY GUIDELINES

In order to determine the clinical utility of gene test(s), all of the following information must be submitted for review. If any of these items are not submitted, it could impact our review and decision outcome:

1. Name of the genetic test(s) or panel test
2. Name of the performing laboratory and/or genetic testing organization (more than one may be listed)
3. The exact gene(s) and/or variant(s) being tested
4. Relevant billing codes
5. Brief description of how the genetic test results will guide clinical decisions that would not otherwise be made in the absence testing
6. Medical records related to this genetic test:
   - History and physical exam including any relevant diagnoses related to the genetic testing
   - Conventional testing and outcomes
   - Conservative treatments, if any

DEFINITIONS

Fetal tissue may consist of fetal tissue, a formed fetus, or placental tissue derived from the fetus, depending on the stage of pregnancy at the time of the fetal loss.

Early pregnancy loss or miscarriage is considered to be a pregnancy loss that occurred at or before 20 weeks of gestational age.[1,2]

CROSS REFERENCES

1. Preimplantation Genetic Testing, Genetic Testing, Policy No. 18
2. Genetic and Molecular Diagnostic Testing, Genetic Testing, Policy No. 20
3. Noninvasive Prenatal Testing to Determine Fetal Aneuploidies and Microdeletions using Cell-Free DNA, Genetic Testing, Policy No. 44
5. Evaluating the Utility of Genetic Panels, Genetic Testing, Policy No. 64
6. Whole Exome and Whole Genome Sequencing, Genetic Testing, Policy No. 76
7. Invasive Prenatal (Fetal) Diagnostic Testing Using Chromosomal Microarray Analysis (CMA), Genetic Testing, Policy No. 78
8. Reproductive Carrier Screening for Genetic Diseases, Genetic Testing, Policy No. 81

BACKGROUND

PREGNANCY LOSS: ETIOLOGY AND EVALUATION

Early Pregnancy Loss
Pregnancy loss is common, occurring in at least 15% to 25% of recognized pregnancies. Most pregnancy loss occurs early in the pregnancy, most often by the end of the first trimester or early second trimester. Pregnancy loss that occurs before the 20th week of gestation is referred to as a spontaneous abortion, early pregnancy loss, or miscarriage. While a wide range of factors can lead to early pregnancy loss, genetic causes are thought to be the predominant cause: when products of conception (POC) are examined, it is estimated that 60% of early pregnancy losses are associated with chromosomal abnormalities, particularly trisomies and monosomy X.[2,3] The increasing risk of trisomies with maternal age contributes to the increased risk of early pregnancy loss with increasing maternal age.

Recurrent pregnancy loss, defined by the American Society for Reproductive Medicine (ASRM) as two or more failed pregnancies, is less common, occurring in approximately 5% of women.[1] Recurrent pregnancy loss may be related to cytogenetic abnormalities, particularly balanced translocations, uterine abnormalities, thrombophilias, including antiphospholipid syndrome, and metabolic/endocrinologic disorders such as uncontrolled diabetes and thyroid disease. Estimates for the frequency of various underlying causes of recurrent pregnancy loss vary widely, with ranges from 2% to 6% for cytogenetic abnormalities, 8% to 42% for antiphospholipid antibody syndrome, and 1.8% to 37.6% for uterine abnormalities.[2] It is likely that the risk of cytogenetic abnormalities is lower in recurrent early pregnancy loss than in isolated spontaneous early pregnancy loss.

Clinicians and patients may undertake an evaluation for the cause of a single or recurrent early pregnancy loss for several reasons. The knowledge that an early pregnancy loss is secondary to a sporadic genetic abnormality may provide parents with reassurance that there was nothing that they did or did not do that contributed to the loss, although the magnitude of this benefit is difficult to quantify. For couples with recurrent pregnancy loss and evidence of a structural genetic abnormality in one of the parents, preimplantation genetic diagnosis with transfer of unaffected embryos or the use of donor gametes might be considered for therapy. These therapies might be considered for couples with recurrent pregnancy loss without evidence of a structural genetic abnormality in one of the parents; guidelines on the management of recurrent pregnancy loss from ASRM state that “treatment options should be based on whether repeated miscarriages are euploid, aneuploid, or due to an unbalanced structural rearrangement and not exclusively on the parental carrier status.” Finally, among patients FA who are found to have a potential nongenetic underlying cause of recurrent pregnancy loss, such as antiphospholipid syndrome, cytogenetic analysis of pregnancy losses may provide evidence that the miscarriages were not due to treatment failure.[4]

Genetic testing of POC, if possible, is recommended by several reproductive health organizations. A committee opinion from ASRM recommends that the assessment of recurrent pregnancy loss include peripheral karyotyping of the parents and states that karyotypic analysis of POC may be useful in the setting of ongoing therapy for recurrent pregnancy loss.[2] The National Society of Genetic Counselors convened a multidisciplinary Inherited Pregnancy Loss Working Group. It recommended that, for the genetic evaluation of couples with recurrent pregnancy loss, when possible, chromosomal analysis on fetal tissue from POC should be pursued.[3]

Late Pregnancy Loss

Fetal loss that occurs later in pregnancy, after 20 weeks of gestation, may be referred to as intrauterine fetal demise (IUFD), stillbirth, or intrauterine fetal death. In 2004, IUFD occurred in...
6.2 of 1000 births in the United States, representing about 60% of perinatal mortality. IUFD may be related to a range of disorders, including genetic disorders in the fetus, maternal infection, coexisting maternal medical disorders (e.g., diabetes, antiphospholipid antibody syndrome, heritable thrombophilias), and obstetric complications, although, in many cases, the precise cause is unidentifiable. Chromosomal or genetic abnormalities can be found in 8% to 13% of IUFD, most commonly aneuploidies. In one large series of IUFD (N=1025), cytogenic abnormalities were detected in 11.9%.[5]

The American College of Obstetrics and Gynecology recommends that evaluation after an IUFD includes examination of the stillborn fetus, along with examination of the placenta and umbilical cord and genetic testing for all IUFD (after parental permission is obtained). Other evaluation should be based on maternal history and may include evaluation for thyroid disorders, systemic lupus erythematosus, and infections.[6]

Some motivations for evaluation for a cause of IUFD are similar to those for earlier pregnancy loss. Although both early and later pregnancy losses may cause grief for the mother and her family, IUFD can be particularly devastating. Information about the cause of the pregnancy loss may be important in counseling women about their recurrence risk. In low-risk women with an unexplained IUFD, the risk of recurrence is 7.8 to 10.5 of 1000 live births, but this increases to 21.8 per 1000 live births in women with a history of fetal growth restriction. Identification of a heritable genetic variant in a fetus may prompt testing in the parents; if a heritable variant is identified, parents may pursue preimplantation genetic diagnosis in future pregnancies.

GENETIC ABNORMALITIES IN MISCARRIAGE AND IUFD

Genetic disorders are generally categorized into three main groups: single gene, chromosomal, and multifactorial. Single-gene disorders (also known as monogenic disorders) result from errors in a specific gene, whereas those that are chromosomal include larger aberrations that are numerical or structural. Evidence about specific abnormalities in miscarriages and IUFD is somewhat limited. However, it is estimated that 60% of early pregnancy losses are associated with chromosomal abnormalities, particularly trisomies and monosomy X. For later pregnancy losses, aneuploidies are most common in the 8% to 13% of tested IUFD that have an identified chromosomal or genetic abnormality. Karyotypic abnormalities are identified in 6% to 12% of IUFD.[7] Rates of single-gene disorders in IUFD are less well-quantified. However, of stillborn fetuses who undergo autopsy, 25% to 35% are identified to have single or multiple malformations or deformations; of these, 25% have an abnormal karyotype, but other single-gene disorders are suspected to occur in a high proportion of stillborn fetuses with malformations.

Traditionally, genetic evaluation of the POC after a miscarriage is conducted by karyotyping of metaphase cells after cells are cultured in tissue. Karyotyping can identify whole chromosome aneuploidies and large structural rearrangements. However, only visible rearrangements are likely to be identified using this method (down to a resolution of 5-10 Mb), so smaller genetic variants may not be detected. In addition, karyotype requires culturing the target cells, which may fail or be infeasible, particularly for formalin-preserved samples. In addition, there is the potential for maternal cell contamination, which may occur if the POC tissue is not separated from the maternal decidua before culturing, or if there is poor growth of noneuploid cells from the POC tissue, thereby allowing maternal cell overgrowth. The potential for maternal cell contamination makes it impossible to know if a normal female (46 XX) karyotype testing result
is due to a normal fetal karyotype or a maternal karyotype. In one study that included 103 first trimester miscarriages, culture failure occurred in 25% of cases.[8]

**CHROMOSOMAL MICROARRAY ANALYSIS TESTING**

There has been interest in using alternative genetic testing methods, particularly array comparative genomic hybridization (aCGH), to detect chromosomal or other genetic abnormalities in the evaluation of miscarriages and IUFD.

**Types of Chromosomal Microarray Analysis Technologies**

Several types of microarray technology are in current clinical use, primarily aCGH and single-nucleotide polymorphism (SNP) microarrays. Comparative genomic hybridization (CGH) chromosomal microarray analysis (CMA) analysis detects copy number variants (CNVs) by comparing a reference genomic sequence with the patient (“unknown”) sequence in terms of binding to a microarray of cloned (from bacterial artificial chromosomes) or synthesized DNA fragments with known sequences. The reference DNA and the unknown sample are labelled with different fluorescent tags, and both samples are cohybridized to the fragments of DNA on the microarray. Computer analysis is used to detect the array patterns and intensities of the hybridized samples. If the unknown sample contains a deletion or duplication of genetic material in a region contained on the reference microarray, the sequence imbalance is detected as a difference in fluorescence intensity.

In SNP-based CMA testing, a microarray of SNPs, which may include hundreds of thousands of SNPs, is used for hybridization. In contrast with aCGH, a reference genomic sequence is not used. Instead, only the “unknown” sample is hybridized to the array platform, and the presence or absence of specific known DNA sequence variants is evaluated by signal intensity to provide information about copy numbers. In some cases, laboratories confirm CNVs detected on CMA with an alternative technique, such as fluorescence in situ hybridization or flow cytometry.

Microarrays also vary in breadth of coverage of the genome that they include. Targeted CMA provides coverage of the genome with a concentration of sequences in areas with known, clinically significant CNVs. In contrast, whole-genome CMA allows the characterization of large numbers of genes, but with the downside that analysis may identify large numbers of CNVs of undetermined significance.

**CMA Compared With Karyotyping**

CMA has several advantages over karyotyping, including improved resolution (detection of smaller chromosomal variants that are undetectable using standard karyotyping), and therefore can result in potentially higher rates of detection of pathogenic chromosomal abnormalities. Array CGH can detect CNVs for larger deletions and duplications, including trisomies. However, CMA based on aCGH cannot detect balanced translocations or diploid, triploid, and tetraploid states, or sequence inversions because they are not associated with fluorescence intensity change. SNP-based CMA, in addition to detecting deletions and duplications, can detect runs of homozygosity, which suggests consanguinity, triploidy, and uniparental disomy.

CMA also has the advantage of not requiring successful cell culture, so it may be more likely to yield a result in cases where karyotyping is technically unsuccessful due to failed culture. In
the case of testing of specimens from early miscarriage, CMA may also be used to rule out maternal cell contamination, if a fetal sample is compared with a maternal sample.

CMA has the disadvantage of higher rates of detection of variants of uncertain significance. The American College of Medical Genetics (ACMG) has published guidelines on the interpretation and reporting of CNVs in the postnatal setting. ACMG recommends that laboratories performing array-based assessment of CNVs track their experience with CNVs and document pathogenic CNVs, CNVs of uncertain significance, and CNVs determined to represent benign variation based on comparisons with internal and external databases.[9]

COMMERCIALLY AVAILABLE TESTS

Natera Inc. (San Carlos, CA) offers the Anora® miscarriage test, which uses a SNP-based array system for testing of POC. The test includes the company's proprietary "Parental Support Technology," which uses a DNA sample from one or both parents as a reference to the POC sample. This comparison can identify maternal cell contamination, uniparental disomy, and the parent of origin of a fetal chromosome abnormality. According to a description of the “Parental Support” algorithm,[10] the algorithm uses the

"SNP array data to calculate the relative amounts of each of the two alleles at each SNP. At heterozygous loci, disomic chromosomes are expected to have SNP ratios of approximately 50%, trisomic chromosomes are expected to have SNP ratios of approximately 33% and 66%, and monosomic chromosomes are expected to have only homozygous loci. For each chromosome, the algorithm compares the observed SNP data to each of the expected alleles for the possible ploidy states and determines which is most likely."

According to the manufacturer’s website, the test reports the following abnormalities, including the parent of origin of any anomaly when a parental sample has been submitted:[11]

- Any whole chromosome aneuploidy.
- Triploidy.
- Tetraploidy where one parent contributed one set of chromosomes and the other parent contributed the other three. Tetraploidy when parental contribution is equal cannot be detected.
- Uniparental disomy.
- Interstitial deletions and duplications greater than 5 Mb.
- Any terminal deletion or duplication, as it could be an indication for a balanced translocation.
- Deletions of 1 Mb or greater and duplications of 2 Mb or greater are reviewed individually by a genetic counselor/geneticist and reported if the potential cause of a miscarriage or recurrence risk implications are identified.
- Any of the following deletions and duplications, when identified:
  - 1p36 deletion
  - 1q21.1 deletion (epilepsy)
  - 2q37 deletion
  - 3q29 terminal deletion
  - 4p16.3 deletion (Wolf-Hirschhorn syndrome)
  - 5p15.2 deletion (cri du chat)
  - 7q11.23 deletion (Williams syndrome syndrome)
o 8q23.2-8q24.1 deletion (Langer-Giedion syndrome)
o 9q34 deletion
o 11p13-14 deletion (WAGR syndrome)
o 11q24.1 deletion (Jacobsen syndrome)
o 10p13-p14 deletion (DiGeorge syndrome)
o 15q11-q13 deletion (Prader-Willi/Angelman syndrome)
o 16p11.2 deletion (epilepsy)
o 17p11.2 deletion (Smith-Magenis syndrome)
o 17p13.3 deletion (Miller-Dieker syndrome)
o 17q21.31 deletion
o 22q13 deletion (Phelan-McDermid syndrome)
o 22q11.2 deletion (DiGeorge syndrome/velocardiofacial syndrome)
o 22q11.2 duplication
o Xq28 deletion (MECP2 deletion)
o Xq28 duplication (MECP2 duplication)

CombiMatrix (Irvine, CA) offers the CombiSNP™ Array for Pregnancy Loss, which is used to test fresh tissue samples, formalin-fixed, paraffin-embedded tissue samples, or unstained slides. According to the manufacturer’s website, the CombiSNP Array is a high-resolution SNP microarray that can detect triploidy, numeric chromosome abnormalities, unbalanced structural rearrangements, microdeletion/ duplication syndromes, long stretches of homozygosity, which can indicate shared ancestry or uniparental disomy, and maternal cell contamination. The company also offers maternal cell contamination studies.[12]

GeneDx offers the Whole Genome Chromosomal Microarray for Products of Conception test, which is a SNP and aCGH that has whole genome aCGH coverage with oligonucleotide probes for the detection of CNVs and SNP probes to detect runs of homozygosity, which may indicate uniparental disomy.

Multiple laboratories offer CMA testing for prenatal samples that is not specifically designed for testing of POC.

REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA). The Anora® miscarriage test, the CombiSNP™ Array for Pregnancy Loss, the CombiBAC™ Array, and the GeneDx Whole Genome Chromosomal Microarray for Products of Conception, along with other chromosomal microarray analysis testing platforms currently available are LDTs available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

EVIDENCE SUMMARY

Human Genome Variation Society (HGVS) nomenclature[13] is used to describe variants found in DNA and serves as an international standard. It is being implemented for genetic testing medical evidence review updates starting in 2017. According to this nomenclature, the term “variant” is used to describe a change in a DNA or protein sequence, replacing previously-used terms, such as “mutation.” Pathogenic variants are variants associated with disease, while
benign variants are not. The majority of genetic changes have unknown effects on human health, and these are referred to as variants of uncertain significance.

The use of chromosomal microarray analysis (CMA) for the evaluation of products of conception and pregnancy loss has been established as standard of care primarily due to clinical consensus for the following situations:

- pregnancy loss after 20 weeks of gestation
- pregnancy loss less than or equal to 20 weeks of gestation when there is a maternal history of recurrent pregnancy loss

Therefore, evidence for the above indications with medical necessity criteria will no longer be reviewed. Only situations considered investigational will be reviewed for evidence.

Although the clinical validity of most diagnostic genetic tests are evaluated based on their ability to diagnosing clinically defined disease, for the purposes of assessment of POC, the diagnosis of a known chromosomal or genetic abnormality in the setting of pregnancy loss may serve as a surrogate end point. The results of CMA can be compared directly with karyotyping, but there is no independent reference standard that can be used to determine the performance characteristics of each test.

**ANALYTIC VALIDITY**

In general, CMA has a high analytic validity for detecting copy number variants (CNVs), in most instances greater than 95%. Since the analytical validity of CMA has been established, it will not be reviewed further.

**CLINICAL VALIDITY**

Although the clinical validity of most diagnostic genetic tests are evaluated based on their ability to diagnosing clinically defined disease, for the purposes of assessment of POC, the diagnosis of a known chromosomal or genetic abnormality in the setting of pregnancy loss may serve as a surrogate end point. The results of CMA can be compared directly with karyotyping, but there is no independent reference standard that can be used to determine the performance characteristics of each test. Below are studies that focus on the use of CMA for evaluating products of conception or pregnancy loss at 20 weeks gestation or less.

**Diagnostic Accuracy of CMA**

In a 2017 systematic review, Pauta evaluated the added value of CMA analysis over karyotyping in early pregnancy loss.\(^{[14]}\) Twenty-three studies were published between January 2000 and April 2017 that met the inclusion criteria. This included 5520 pregnancy losses up to 20 weeks. When CMA and karyotyping were performed concurrently, informative results were provided by CMA in 95% (95%CI: 94%-96%) of cases and by karyotyping in 67% (95%CI: 64%-70%) of cases. The incremental yield of pathogenic CNV by CMA over karyotyping was 2%.

In 2014, Dhillon reported results from a systematic review and meta-analysis of studies that compared CMA with conventional karyotyping in the evaluation of miscarriage.\(^{[15]}\) The authors included nine studies that reported results from CMA on POC following miscarriage alongside conventional karyotyping. Overall, there were 314 miscarriage samples in the included studies. One study was included that assessed 41 cases of spontaneous pregnancy loss <20 weeks of
gestation, and two studies assessed first-trimester spontaneous miscarriage (n=14, 86). These studies were not analyzed separately for the others. In pooled analysis, the overall agreement between karyotype and CMA results was 86.0% (95% confidence interval [CI], 77.0% to 96.0%), with high homogeneity across the studies (Cochrane Q, I²=0.2%). CMA detected 13% (95% CI, 8.0% to 21.0%) additional chromosomal abnormalities not detected by karyotyping (including both likely pathogenic variants and variants of uncertain significance [VOUS or VUS]). Conventional karyotyping detected 3% (95% CI, 1.0% to 10.0%) additional abnormalities not detected by CMA. Among five studies that reported VOUS, the pooled chance of having a VOUS was 2% (95% CI, 1.0% to 10.0%). This systematic review demonstrated good overall agreement between CMA and karyotype in the analysis of miscarriage specimens. However, the CI around the estimate of VOUS rate was large, indicating uncertainty regarding the true rate. Further research is required to determine whether CNVs found in POC are pathogenic or benign.

A number of additional studies not included in the Dhillon systematic review have compared CMA with karyotyping.

Popescu (2018) reported on a single-center prospective cohort study of 100 patients.[16] The study compared the percent of patients that learned a cause of recurrent pregnancy loss from the standard American Society for Reproductive Medicine (ASRM) evaluation, which included karyotyping, for recurrent miscarriage versus from ASRM evaluation plus CMA evaluation. Patients with two or more pregnancy losses. A definite or probable cause of pregnancy loss was identified in 95% of patients with ASRM plus CMA evaluation. The ASRM workup alone identified probable cause of pregnancy loss in 45% of patients whereas the CMA evaluation alone identified probable cause of pregnancy loss in 67% of patients. The final 5% of patients did not have a probable or definitive cause of pregnancy loss identified.

In 2014, Lathi reported results from a comparison of a SNP-based array with informatics assistance (“Parental Support” algorithm previously described) with conventional karyotyping in 30 first-trimester miscarriage samples.[17] CMA was conducted using a single-nucleotide polymerase (SNP)–based microarray, which measures about 300,000 SNPs across the genome (approximately one SNP every 10 Kb). The “Parental Support” technique compares results from the POC sample with parental samples to determine the number and origin of each chromosome in the POC sample. On conventional karyotype, 63% of samples were chromosomally abnormal, with autosomal trisomies as the most common abnormality. All 46 XX samples on karyotype were confirmed to be from fetal tissue on microarray analysis. Four samples were discordant between CMA and karyotype, including one case of whole genome duplication and one balanced translocation, both of which would not be expected to be detected on microarray, and two additional discrepancies that were attributed to sampling error, tissue mosaicism, or culture artifact.

In 2009, Menten reported results of an evaluation of 100 pregnancy losses with conventional karyotyping, flow cytometry, and array comparative genomic hybridization (aCGH).[18] Fifty samples were collected from first-trimester losses and 34 samples from second-trimester. Array CGH was performed using an investigator-developed bacterial artificial chromosome microarray at a resolution of approximately 1 Mb. Overall, on conventional karyotyping, normal karyotypes were found in 11 male and 44 female cases. Seventeen of the fifty (34%) first-trimester samples were found to be abnormal by CMA, while only six and the 34 (18%) of the second-trimester samples were found to be abnormal. However, the authors state that contamination from maternal decidua in the first trimester can be a potential technical issue.
In 2006, Hu conducted genetic analysis by both CGH and karyotyping in 38 POC from early pregnancy losses.[19] Culture of chorionic villi and examination of metaphase chromosomes was attempted in all samples, but cytogenic analysis was technically successful in only 31 samples. Of the 31 samples successfully karyotyped, 14 were diagnosed to be aneuploides, including four with trisomy 21, two each with trisomies 13 and 16, two with monosomy X, and one each with trisomies 7, 20, 18, and 3. An additional two cases of triploidy were detected. On CGH analysis, 17 aneuploidies were identified (14 of those found on the karyotyped samples, along with three cases in samples for which cell culture failed), along with one structural chromosomal abnormality. For the 31 samples that had both tests conducted, there was generally good concordance between the two approaches, with the exception that CGH did not detect the two cases of triploidy.

**YIELD OF CMA IN PREGNANCY LOSS**

**CMA in Early Pregnancy Loss**

Several studies have assessed the use of CMA in the evaluation of early pregnancy loss when standard karyotyping was unsuccessful, or have evaluated the incremental benefit of CMA in the detection of maternal cell contamination.

In 2014, Lathi reported results of a retrospective analysis of the use of CMA in detecting maternal cell contamination on conventional karyotyping in 1222 POC samples from first-trimester miscarriages that were evaluated at the Natera laboratory from January 2010 to August 2011.[10] The POC samples, along with maternal peripheral blood samples, were evaluated with a SNP-based CMA. When CMA results for the POC were 46 XX, a comparison with the maternal genotype fingerprint allowed investigators to determine if results were due to maternal cell contamination. On initial analysis, before comparison with the maternal genotype fingerprint, 48% of POC specimens were chromosomally abnormal, 37% were 46 XX, and 14% were 46 XY. Comparison with maternal bloody genotype indicated that 59% of the 46 XX results were due to maternal cell contamination. The authors suggested that the use of CMA may improve accurate detection of fetal chromosomal abnormalities.

Viaggi (2013) used a whole genome aCGH to evaluate 40 POC samples from first trimester miscarriages that had normal karyotypes to assess for the presence and prevalence of CNVs.[20] Frozen samples were evaluated with aCGH with a resolution of 100 Kb. CNVs were compared with those present in the Database of Genomic Variants (http://projects.tcag.ca/variation), Decipher (http://decipher.sanger.ac.uk), and the Database of Human CNVs (http://gvarianti.homelinux.net/gvarianti/index.php) to differentiate between benign CNVs and possibly pathogenic CNVs. Forty-five CNVs, corresponding to 22 different CNVs, were identified in 31 samples (31/40 [77.5%]). Thirty-one of the 45 CNVs identified (68%) were defined as common CNVs. When the CNVs were compared with control CNVs reported in the Database of Genomic Variants, seven CNV frequencies were considered statistically different from the control population.

Doria (2009) evaluated aCGH as part of a sequential protocol in the genetic evaluation of 232 spontaneous miscarriages or fetal deaths, 186 of which were from the first trimester, 24 from the second trimester, and 22 from the third trimester.[21] Tissue culture and karyotype was attempted on all specimens; samples that could not be karyotyped were tested with aCGH, followed by additional confirmation with fluorescence in situ hybridization (FISH) confirmation. Culture failure occurred in 25.4% of the cases. Of the 173 (74.6%) with valid karyotypes, 66 of 173 (38.2%) were abnormal: 62 of 66 with numerical abnormalities (single, double, or triple
trisomies, monosomy X, polyploidy, or mosaicism), and five of 66 with structural abnormalities. Array CGH was performed in 58 of 59 cases with culture failure (1 case with insufficient DNA for CGH). Fifteen of the 58 cases were abnormal, with three cases of monosomy X, one case of XY with gain for X, seven cases of trisomy 15, two cases of trisomy 16, and one case each of trisomy 18 and 21. With the addition of FISH testing, four new cases of triploidy were detected. This study suggests that the use of aCGH increases the yield of testing of genetic testing of POC beyond that of standard karyotyping.

Benkhalifa (2005) evaluated 26 samples from first-trimester miscarriages that failed to divide in routine cytogenetic studies with array used CMA methods with array CGH. The aCGH method used involved human genomic microarrays containing 2600 cloned areas spanning chromosome subtelomeric regions and critical areas spaced about 1 Mb along each chromosome. Of the 26 samples that failed to divide in routine cytogenetics, 15 had an abnormal genetic profile on aCGH. Abnormalities that are highly prevalent on routine karyotyping (trisomy 16, monosomy X, triploidy, which are estimated to account for >55% of cytogenetically abnormal findings in routine karyotyping) were relatively uncommon among the 15 abnormal samples, with instance of monosomy 16 and two instances of monosomy X.

Barrett (2001) evaluated aCGH-based CMA in 368 specimens from first- and second-trimester spontaneous abortions, of which gestational age and degree of tissue maceration was available for 276. Genetic abnormalities were detected in 206 cases, with complete or partial aneuploidy involving trisomy in 85.5%, monosomy X in 9.2%, and structural rearrangements in 5.3%. Samples were also analyzed with traditional cytogenetics, but direct comparisons between CGH and cytogenetics were not reported.

A number of studies have reported outcomes from CMA of POC in various patient populations where karyotyping was not performed.

In 2016, Wang reported on a prospective study assessing the clinical application of CMA testing for first-trimester pregnancy loss, successfully analyzing 551 fresh miscarriage specimens using single-nucleotide polymorphism (SNP) array. Among the specimens, 2.9% (16/551) had significant maternal cell contamination and were excluded from the study. Clinically significant chromosomal abnormalities were identified in 295 (55.1%) cases, including 214 (40%) with aneuploidy, 40 (7.5%) with polyploidy, 19 (3.6%) with partial aneuploidy, 12 (2.2%) with pathogenic microdeletion/microduplication, and 10 (1.9%) with uniparental isodisomy (isoUPD). Variants of uncertain significance were obtained in 15 cases (2.8%). The authors concluded that SNP array is a reliable, robust, and high-resolution technology for genetic diagnosis of miscarriage in clinical practice.

In 2016, Wou reported on a three-year retrospective study that analyzed tissue from products of conception and perinatal losses using QF-PCR and microarray. CMA was performed mostly in samples with normal QF-PCR results. Of the 1071 informative specimens analyzed, 30.8% (n = 330) were positive for chromosomal abnormalities, with 57.6% (n = 190) of the abnormalities being detected by QF-PCR and 42.4% (n = 140) by aCGH. In addition high-resolution aCGH enabled an additional diagnostic yield of 36 cases of microdeletions and/or microduplications (10.9%) in specimens found to be abnormal by QF-PCR and 3.4% of all successfully analyzed specimens. Gestational age was known in 940 specimens. The study reported that the highest rate of chromosomal abnormalities (a combined analysis of QF-PCR and aCGH abnormalities) was observed in the first trimester (<12 weeks) with 67.6% being considered pathogenic. The difference in proportions of pathogenic findings across trimesters.
was statistically significant (p < 0.001) with the greater proportion of findings being in the first trimester.

In 2015, Maslow evaluated the yield of SNP-based array for determining chromosome number in paraffin-fixed POC compared with a standard evaluation for couples with recurrent first-trimester pregnancy losses.\cite{26} Eligible patients previously had analysis of chromosome number and screening tests recommended by the American Society for Reproductive Medicine (ASRM) for recurrent pregnancy loss, including parental karyotypes, maternal serum testing for antiphospholipid antibodies, thyrotropin, and prolactin, and a uterine cavity evaluation via sonohysterogram or hysterosalpingogram. Forty-two women with a total of 178 first-trimester losses were included, with 62 paraffin-embedded POC samples available. SNP-based microarray was able to determine a fetal chromosome number in 44 of 62 (71%) of samples, 25 (57%) of which were noneuploid. Recurrent pregnancy loss screening was normal in 35 of 42 (83%) participants. The detection rate for any cause of pregnancy loss was significantly higher with SNP microarray (0.50; 95% CI, 0.36 to 0.64) than with the ASRM-recommended recurrent pregnancy loss evaluation (0.17; 95% CI, 0.08 to 0.31, p=0.002).

Also in 2015, Romero reported on types of genetic abnormalities found on CMA in early pregnancy losses (<20 weeks of gestation) among 86 women.\cite{27} Thirteen (14.9%) of POC samples were excluded because placental villi or fetal tissue could not be identified with certainty and nine were excluded due to complete maternal cell contamination, leaving a sample of 64 for analysis. The overall prevalence of aneuploidy and pathogenic CNV or VOUS was 43.8% (28/64). Excluding the two cases with VOUS, rates of pathogenic CNV or aneuploidy differed by gestational age: 9.1%, 69.2%, and 28.0% of pre-embryonic, embryonic, and fetal samples, respectively (p<0.01). Aneuploidy was the most common abnormality, occurring in 37.5% (24/64) cases.

In the largest such study identified, Levy (2014) reported results of SNP microarray analysis of 2447 consecutively received POC samples, of which 2400 were fresh samples.\cite{28} Of the fresh samples, 2392 (99.7%) were 20 weeks of gestation or less, and 1861 (77.6%) had no or negligible maternal cell contamination. The authors used a 10-Mb cutoff to estimate the threshold of detection for routine karyotyping in POC samples. At the resolution of conventional karyotyping, 1106 (59.4%) showed classical cytogenetic abnormalities. Of the remaining 755 samples considered normal at the karyotype level, 33 (4.4%) had a CNV (microdeletion or microduplication); 12 (36.4%) were considered clinically significant and the remaining were considered VOUS.

In 2014, Mathur reported results from CMA testing in preserved POC samples from 58 women with 77 miscarriage specimens who were evaluated at a single recurrent pregnancy loss clinic.\cite{29} All women had a history of recurrent pregnancy loss, defined as two or more ultrasound-documented miscarriages at less than 10 weeks of gestation. Samples were evaluated with CGH; if results were 46 XX, the genotype of the POC was compared with the maternal genotype at several highly polymorphic loci through microsatellite analysis (MSA) to determine if the 46 XX results were consistent with maternal cell contamination. Sixteen samples (21%) yielded uninformative results due to minimal pregnancy tissue (n=9), poor quality DNA (n=2), or confirmed maternal cell contamination (n=2). CGH was considered informative in 61 cases (79%), with 22 noneuploid and 39 euploid. Thirty-three of the euploid specimens were 46 XX, 11 of which were not sent for reflex MSA. The author concluded that CMA testing of preserved POC is technically feasible, including in cases where karyotyping had failed due to cell growth failure, which had occurred in eight samples evaluated.
Warren (2009) conducted a prospective case series to evaluate results from aCGH in POC from 35 women who had pregnancy loss between 10 and 20 weeks of gestation with either normal karyotype (n=9) or no conventional cytogenetic testing (n=26). Thirty-five samples were from fresh tissue obtained at the time of pregnancy loss when dilatation and curettage was performed; the remainder was from paraffin-embedded tissue. Samples were assessed with a whole genome bacterial artificial chromosome array chip. Clones that demonstrated copy number changes in the fetal tissue were compared against known copy number change regions in the Database of Genomic Variants, and the internal database of apparently benign copy number changes maintained by the University of Utah CGH laboratory. When CNVs were detected, parental samples were assessed with the same array chip, and CNVs present in fetal tissue but not parental DNA were defined as de novo CNVs. Samples with de novo CNVs on the bacterial artificial chromosome chip were further analyzed with an oligonucleotide microarray chip with an average resolution of 6.4 Kb for more accurate characterization. DNA was successfully isolated in 30 cases (all from the fresh tissue samples). De novo CNVs were detected in six of the 30 (20%) cases using the bacterial artificial chromosome array and confirmed in four of 30 (13%) cases using the oligonucleotide array.

In 2007, Azmanov evaluated samples from 106 first- (n=3) and second-trimester (n=23) miscarriages with aCGH-based CMA. Although the specific weeks of gestational age are not reported, most samples were from early miscarriages, including eight blighted ova and 75 missed abortions, with 23 second-trimester spontaneous abortions. In the entire sample, 40 of 106 (37.7%) demonstrated chromosomal abnormalities, with 82.5% numerical abnormalities (47.5% aneuploidy, 25.0% monosomy X, 10.0% hyperdiploidy) and 17.6% structural aberrations.

CMA in IUFD

The use of CMA for evaluating products of conception for IUFD is documented in a number of large nonrandomized studies. In studies that used CMA on samples that had been previously found to have normal karyotypes, approximately 13% were found to have pathogenic results via CMA testing.

In a large study that compared CMA with karyotype in the evaluation of 532 cases of IUFD. Of the karyotypes attempted, 375 (70.5%) yielded a result. Of those, 31 of 375 (8.3%) were classified as abnormal, with trisomy 21 (n=9), trisomy 18 (n=8), trisomy 13 (n=2), and monosomy X (n=5) representing the most common abnormalities. CMA yielded results in 465 (87.4%) of samples, significantly more than were successful karyotyped (p<0.001). Of those, 32 (6.9%) were aneuploidy, 12 (2.6%) were considered a pathogenic variant, and 25 (5.4%) were considered a VOUS. Nine pathogenic variants on CMA were detected in stillbirths with normal karyotypes. CMA detected aneuploidy in seven cases of the 157 in which karyotyping was unsuccessful.

Section Summary: Clinical Validity

The evidence related to the clinical validity of CMA comes primarily from studies that compared genetic testing results from CMA with conventional karyotype, and from several studies that evaluated the yield of CMA in patients with a normal or unsuccessful karyotype. These studies suggest that CMA has good concordance with karyotype for detection of aneuploidy and is more likely to yield results than conventional karyotyping given the need for cell culture for karyotyping. Studies on the yield of testing in early pregnancy losses suggests that aneuploidies are the most common abnormality detected, CMA may detect abnormalities
not detected on karyotype. Relatively few studies have reported CMA outcomes in late pregnancy losses, but they suggest that CMA is more likely to yield a result than conventional karyotyping.

**CLINICAL UTILITY**

**Changes in Patient Management Following CMA**

Changes in management that could result from CMA testing include changes in additional testing to evaluate for causes of a pregnancy loss or changes in the management of future pregnancies, such as the decision to undertake preimplantation genetic testing. No empirical studies identified evaluated changes in management that occurred as a result of CMA testing in miscarriage or IUFD.

One argument for genetic evaluation (karyotype or CMA) in POC in cases of recurrent pregnancy loss is that an abnormal genetic evaluation would potentially forestall an evaluation for other causes of recurrent pregnancy loss, which might include assessment of the uterine cavity, thyroid function testing, and testing for antiphospholipid antibodies. In the study by Maslow (described above), the yield of testing using a SNP microarray in recurrent pregnancy loss was higher than the yield of other recommended testing (some of which are potentially invasive).[26]

**Improvement in Patient Outcomes Following CMA**

Several potential health-related outcomes result from CMA testing POC in pregnancy loss. These outcomes are the same for both early and late pregnancy loss. Knowledge of the cause of the loss may lead to reduced parent distress or anxiety. For couples with recurrent pregnancy loss, preimplantation genetic diagnosis with transfer of unaffected embryos or the use of donor gametes might be considered for therapy. No studies identified reported whether the use of CMA is associated with changes in parental mental health outcomes.

No studies identified addressed whether CMA of POC is associated with changes in management or future successful pregnancies.

**Section Summary: Clinical Utility**

Although there are several ways in which CMA of fetal tissue in early pregnancy loss has potential for clinical utility, including leading to changes in diagnostic testing, reduced parental distress, or preimplantation genetic diagnosis, no studies identified directly demonstrated changes in outcomes.

**SUMMARY OF EVIDENCE**

The evidence for the use of chromosomal microarray analysis (CMA) testing of fetal tissue in individuals who have pregnancy loss suggests that CMA has a high rate of concordance with karyotyping. For both early and late pregnancy loss, CMA is more likely to yield a result than karyotyping. Other studies have reported that CMA detects a substantial number of abnormalities in patients with normal karyotypes, although the precise yield is uncertain and likely varies based on gestational age. Rates of variants of unknown significance in CMA testing of miscarriage samples are not well characterized. Potential benefits from identifying a genetic abnormality in a miscarriage or intrauterine fetal demise include reducing emotional distress for families, altering additional testing that is undertaken to assess for other causes of
pregnancy loss, and changing reproductive decision making for future pregnancies. The potential for clinical utility for CMA testing of fetal tissue in pregnancy loss is parallel to that for obtaining a karyotype of fetal tissue in pregnancy loss, which is recommended by a number of organizations. While no studies identified directly demonstrated whether or how patient management is changed based on CMA testing of POC from early or late pregnancy losses, or how patient outcomes are improved, the available evidence suggests that, for pregnancy loss at 20 weeks gestation or less in recurrent pregnancy loss, and after 20 weeks gestation in pregnancy loss, CMA would be expected to perform as well as or better than standard karyotyping.

**PRACTICE GUIDELINE SUMMARY**

**AMERICAN COLLEGE OF OBSTETRICS AND GYNECOLOGISTS (ACOG) AND THE SOCIETY FOR MATERNAL-FETAL MEDICINE (SMFM)**

In 2016, the American College of Obstetrics and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine published a joint committee opinion (No. 682) on the use of CMA testing in obstetrics and gynecology, stating the following:[35]

“Chromosomal microarray analysis of fetal tissue (ie, amniotic fluid, placenta, or products of conception) is recommended in the evaluation of intrauterine fetal death or stillbirth when further cytogenetic analysis is desired because of the test’s increased likelihood of obtaining results and improved detection of causative abnormalities.”

**AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE**

In 2012, the American Society for Reproductive Medicine issued a committee opinion on the evaluation and treatment of recurrent pregnancy loss.[2] The statement makes the following conclusions about the evaluation of recurrent pregnancy loss:

- “Evaluation of recurrent pregnancy loss can proceed after two consecutive clinical pregnancy losses.”
- Assessment of recurrent pregnancy loss focuses on screening for genetic factors, which may include peripheral karyotype of the parents.
- “Karyotypic analysis of products of conception may be useful in the setting of ongoing therapy for recurrent pregnancy loss.”

**ROYAL COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS**

In 2011, the Royal College of Obstetricians and Gynaecologists issued guidelines on the evaluation and treatment of couples with recurrent first-trimester and second-trimester miscarriage.[36] The guidelines make the following recommendations related to karyotyping in recurrent miscarriage:

- “Cytogenetic analysis should be performed on products of conception of the third and subsequent consecutive miscarriage(s).” (Grade of evidence D [evidence level 3 or 4; or extrapolated from studies rated as 2+; evidence level 4 [expert opinion]).
- “Parental peripheral blood karyotyping of both partners should be performed in couples with recurrent miscarriage where testing of products of conception reports an unbalanced structural chromosomal abnormality.” (Grade of evidence D; Evidence level 3 [nonanalytical studies, eg, case reports, case series]).

GT79 | 15
The research on chromosomal microarray analysis (CMA) testing of fetal tissue is limited. However, practice guidelines recommend CMA testing for pregnancy loss for certain individuals. Therefore, CMA testing may be considered medically necessary at less than or equal to 20 weeks of gestation when there is recurrent pregnancy loss or pregnancy loss after 20 weeks of gestation.

There is not enough research to show that chromosomal microarray analysis (CMA) testing of fetal tissue is helpful for individuals that do not meet the policy criteria. Clinical guidelines only recommend testing for pregnancy loss at less than or equal to 20 weeks of gestation when there is recurrent pregnancy loss, or if there is pregnancy loss after 20 weeks of gestation. Therefore, this testing is considered investigational when policy criteria are not met.

REFERENCES


**CODES**

**NOTE:** The appropriate codes for reporting CMA are 81228 for CMA alone, and 81229 for CMA testing that includes single nucleotide polymorphism (SNP) analysis. It is not appropriate to report code 81422 for CMA.
<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81228</td>
<td>Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)</td>
</tr>
<tr>
<td></td>
<td>81229</td>
<td>Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities</td>
</tr>
<tr>
<td></td>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
<tr>
<td></td>
<td>88271</td>
<td>Molecular cytogenetics; DNA probe, each (eg, FISH)</td>
</tr>
<tr>
<td></td>
<td>88299</td>
<td>Unlisted cytogenetic study</td>
</tr>
<tr>
<td>HCPCS</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

**Date of Origin:** April 2017